# Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-acceptance-of-late-breaking-abstract-for-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting
Ticker: APLT
Company: Applied Therapeutics
Source: Applied Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.appliedtherapeutics.com
## Summary

Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.

## Article Body
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.
## Recent Company News
- 2026-06-25 13:46 EST — [Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting](https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-acceptance-of-late-breaking-abstract-for-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Reports First Quarter 2025 Financial Results](https://biopharmsignal.com/news/APLT/applied-therapeutics-reports-first-quarter-2025-financial-results) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting](https://biopharmsignal.com/news/APLT/applied-therapeutics-presents-full-12-month-clinical-results-and-new-topline-data-from-inspire-phase-2-3-trial-of-govorestat-in-cmt-sord-in-late-breaking-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Announces Key Leadership Appointments](https://biopharmsignal.com/news/APLT/applied-therapeutics-announces-key-leadership-appointments) — Source: Applied Therapeutics
- 2026-06-25 13:46 EST — [Applied Therapeutics Reports Second Quarter 2025 Financial Results](https://biopharmsignal.com/news/APLT/applied-therapeutics-reports-second-quarter-2025-financial-results) — Source: Applied Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)